Browsing Tag
ML-004
2 posts
Will ZEPHYR and IRIS data position MapLight Therapeutics, Inc. as a scalable CNS innovator?
MapLight Therapeutics nears dual CNS data readouts. Discover how ZEPHYR and IRIS could shape its strategy and market positioning.
MapLight Therapeutics sets sights on Nasdaq IPO as CNS pipeline advances toward pivotal trials
MapLight Therapeutics files for Nasdaq IPO to raise $250M for schizophrenia and Alzheimer’s trials. Find out what’s next for this neuroscience innovator.